Last reviewed · How we verify
Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
This is a multi-drug chemotherapy regimen that kills rapidly dividing cancer cells through multiple mechanisms including antimetabolite activity, alkylating damage, and topoisomerase inhibition.
This is a multi-drug chemotherapy regimen that kills rapidly dividing cancer cells through multiple mechanisms including antimetabolite activity, alkylating damage, and topoisomerase inhibition. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients, Lymphomas in pediatric patients.
At a glance
| Generic name | Methotrexate, Cyclophosphamide, Cytarabine, Etoposide |
|---|---|
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Multi-agent chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Methotrexate inhibits dihydrofolate reductase to disrupt nucleotide synthesis; cyclophosphamide is an alkylating agent that cross-links DNA; cytarabine is a cytidine analog that incorporates into DNA and RNA; etoposide inhibits topoisomerase II. Together, these agents target different pathways of cell division and DNA integrity, commonly used in intensive chemotherapy regimens for hematologic malignancies.
Approved indications
- Acute lymphoblastic leukemia (ALL) in pediatric patients
- Acute myeloid leukemia (AML) in pediatric patients
- Lymphomas in pediatric patients
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Mucositis
- Nausea and vomiting
- Alopecia
- Infection
- Hemorrhage
- Secondary malignancy
Key clinical trials
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- BNHL-2015 for Children or Adolescents in China (PHASE2, PHASE3)
- CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (PHASE3)
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: